Connect with us


Plant Medicine Week 2022: Meet The Sponsors

The article Plant Medicine Week 2022: Meet The Sponsors was originally published on Microdose.

The leader in the business of psychedelics, Microdose took…



The article Plant Medicine Week 2022: Meet The Sponsors was originally published on Microdose.

The leader in the business of psychedelics, Microdose took its next step as a leader in industry events with its first European event: Plant Medicine Week in beautiful Malta.

The event took place in April, combined with cannabis industry leader Medcann World Forum. It was a resounding success. Attendees were shown the latest advances from the medical cannabis and psychedelics industries through a mix of case-studies presentations, discussions, Q&A sessions, and exhibitions.

Pulling off such an undertaking wouldn’t be possible without the support of our sponsors, they are crucial to both the event and the future of the psychedelic medicine industry. So it’s an honor for Microdose to give a shout-out to our line-up of sponsors.


Irwin Naturals Emergence is a wholly owned subsidiary of Irwin Naturals, a California based nutraceutical company founded in 1994 by Klee Irwin, and part of the Irwin Naturals Inc (CSE: IWIN) (FRA: 97X) family. Irwin Naturals Emergence plans to offer ketamine-assisted psychedelic treatments to patients suffering from mental health issues and other ailments in Irwin Naturals Emergence clinics across the United States.


MindBio Therapeutics is a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicines to treat a range of debilitating mental health conditions. Clinical trials are underway at the University of Auckland in New Zealand.


PsyRx, a psychedelic pharmaceuticals company based in Israel and Licensed by the Israeli Ministry of Health to conduct R&D in the psychedelic substances Psilocybin and Ibogaine, utilises bioreactor technology to become a leading producer of GMP standard Ibogaine and Psilocybin. PsyRx intends to use these psychedelic substances to launch the development of an anti-depressant drug based on the combination of micro-doses of psychedelics.


IMIO is dedicated to identify and refine the use of psychedelic molecules to better treat chronic pain. The approach is to combine known molecules with our proprietary BTLS drug delivery technology, enabling better penetration of molecules into the brain, reducing the therapeutic dose, providing a safer treatment while minimizing adverse effects.


Med Plant Science is a biotech company focused on the research and development of medicines based on psychedelic substances. The company is licensed to grow, process, extract, and export psychedelic compounds from plants and mushrooms. Med Plant Science is innovating rapid onset psychedelic medications using patented nanoencapsulation technology. This novel approach empowers clinicians to work with more patients and secure better outcomes.


Origin Therapeutics is an actively managed investment issuer providing investors with diverse exposure to the psychedelic industry. The Company’s team of technical and experienced investment professionals has decades of experience managing investment portfolios and has access to a diverse deal pipeline. Origin Therapeutics also supports the companies they invest in with advisory or board positions.


Negev Capital is a psychedelic medical intervention investment fund with assets of USD$20+ million. The Company invests in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. They aim to support those early-stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.


ReaGenics conducts research and development related to cannabis production techniques. It creates cannabinoid profiles in stable laboratory controlled environments by growing cannabis in a plant cell bioreactor. Using the mass-scale multiplication of cannabis plant cells under in-vitro laboratory conditions, the company’s PCBR removes environmental complications by eliminating the need to grow whole plants in order to obtain bulk-scale and botanically derived cannabinoids.


Read More